{"transactions":[{"id":695094,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-06T01:42:11.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":4375,"price":26.1168,"value":114261.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby\nundertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective\nprice within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026."}],"balance_after":717203,"source":{"system":"sec-edgar","filing":"0001628280-26-053753","document":"wk-form4_1785980527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026053753/wk-form4_1785980527.xml","form_type":"4"}},{"id":789422,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-06T22:06:03.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":3172,"price":23.6106,"value":74892.8232,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person's holdings reflect a transfer to ex-spouse pursuant to a domestic relations order."}],"balance_after":720755,"source":{"system":"sec-edgar","filing":"0001801061-26-000003","document":"wk-form4_1778105161.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106126000003/wk-form4_1778105161.xml","form_type":"4"}},{"id":864739,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-04T01:42:43.000Z","date":"2026-02-27","kind":"grant","planned":true,"acquired":true,"shares":266000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":266000,"derivative":{"exercise_price":26.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":266000},"source":{"system":"sec-edgar","filing":"0001628280-26-014327","document":"wk-form4_1772588561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014327/wk-form4_1772588561.xml","form_type":"4"}},{"id":864738,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T01:42:43.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1068,"price":25.9139,"value":27676.0452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":785957,"source":{"system":"sec-edgar","filing":"0001628280-26-014327","document":"wk-form4_1772588561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014327/wk-form4_1772588561.xml","form_type":"4"}},{"id":864737,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T01:42:43.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":36281,"price":25.1606,"value":912851.7286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.6850 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":787025,"source":{"system":"sec-edgar","filing":"0001628280-26-014327","document":"wk-form4_1772588561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014327/wk-form4_1772588561.xml","form_type":"4"}},{"id":864736,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T01:42:43.000Z","date":"2026-02-27","kind":"grant","planned":true,"acquired":true,"shares":102000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Constitute Restricted Stock Units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the \"Vesting Commencement Date\"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":823306,"source":{"system":"sec-edgar","filing":"0001628280-26-014327","document":"wk-form4_1772588561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014327/wk-form4_1772588561.xml","form_type":"4"}},{"id":918864,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-05T00:25:40.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":19833,"price":25.4984,"value":505709.7672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units (\"RSUs\"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the \"Vesting Commencement Date\"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 602 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025."}],"balance_after":721306,"source":{"system":"sec-edgar","filing":"0001628280-26-005570","document":"wk-form4_1770251138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026005570/wk-form4_1770251138.xml","form_type":"4"}},{"id":989555,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-24T23:45:34.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":48945,"price":30.3556,"value":1485754.842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person's holdings reflect a transfer to ex-spouse pursuant to a domestic relations order."}],"balance_after":740537,"source":{"system":"sec-edgar","filing":"0001801061-25-000012","document":"wk-form4_1764027931.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000012/wk-form4_1764027931.xml","form_type":"4"}},{"id":989554,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-24T23:45:34.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":1055,"price":30,"value":31650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026."}],"balance_after":793838,"source":{"system":"sec-edgar","filing":"0001801061-25-000012","document":"wk-form4_1764027931.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000012/wk-form4_1764027931.xml","form_type":"4"}},{"id":1006509,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-05T23:23:59.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":69,"price":25.3991,"value":1752.5379,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.3361 to $25.40, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":794893,"source":{"system":"sec-edgar","filing":"0001801061-25-000010","document":"wk-form4_1762385036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000010/wk-form4_1762385036.xml","form_type":"4"}},{"id":1006508,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-05T23:23:59.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":11478,"price":24.7122,"value":283646.6316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.31 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":794962,"source":{"system":"sec-edgar","filing":"0001801061-25-000010","document":"wk-form4_1762385036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000010/wk-form4_1762385036.xml","form_type":"4"}},{"id":1011151,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-10-30T23:02:20.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":25.0258,"value":1001032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1691, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":806440,"source":{"system":"sec-edgar","filing":"0001801061-25-000008","document":"wk-form4_1761865337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000008/wk-form4_1761865337.xml","form_type":"4"}},{"id":1023944,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-10-03T21:02:42.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":20739,"price":20.0383,"value":415574.3037,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.1826, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":846440,"source":{"system":"sec-edgar","filing":"0001801061-25-000006","document":"wk-form4_1759525359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000006/wk-form4_1759525359.xml","form_type":"4"}},{"id":1023943,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-10-03T21:02:42.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":9261,"price":20.0164,"value":185371.8804,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.045, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":867179,"source":{"system":"sec-edgar","filing":"0001801061-25-000006","document":"wk-form4_1759525359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000006/wk-form4_1759525359.xml","form_type":"4"}},{"id":1023942,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-10-03T21:02:42.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":18.9135,"value":283702.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 3, 2025, by the Reporting Person, with a plan end date of September 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.80 to $19.0101, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":876440,"source":{"system":"sec-edgar","filing":"0001801061-25-000006","document":"wk-form4_1759525359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000180106125000006/wk-form4_1759525359.xml","form_type":"4"}},{"id":1043691,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-10T22:21:50.000Z","date":"2025-09-09","kind":"sale","planned":true,"acquired":false,"shares":504,"price":17.5179,"value":8829.0216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.54, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":891440,"source":{"system":"sec-edgar","filing":"0001787306-25-000136","document":"wk-form4_1757542906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000136/wk-form4_1757542906.xml","form_type":"4"}},{"id":1043690,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-10T22:21:50.000Z","date":"2025-09-08","kind":"sale","planned":true,"acquired":false,"shares":9625,"price":17.5376,"value":168799.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.59, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":891944,"source":{"system":"sec-edgar","filing":"0001787306-25-000136","document":"wk-form4_1757542906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000136/wk-form4_1757542906.xml","form_type":"4"}},{"id":1073852,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-05T22:29:05.000Z","date":"2025-08-04","kind":"sale","planned":true,"acquired":false,"shares":11547,"price":14.3266,"value":165429.2502,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.965 to $14.675, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":901569,"source":{"system":"sec-edgar","filing":"0001787306-25-000119","document":"wk-form4_1754432942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000119/wk-form4_1754432942.xml","form_type":"4"}},{"id":1112806,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-12T20:53:13.000Z","date":"2025-06-10","kind":"gift","planned":false,"acquired":true,"shares":997,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of these securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee."}],"balance_after":25410,"source":{"system":"sec-edgar","filing":"0002065881-25-000013","document":"wk-form4_1749761587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000206588125000013/wk-form4_1749761587.xml","form_type":"4"}},{"id":1112805,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-12T20:53:13.000Z","date":"2025-06-10","kind":"gift","planned":false,"acquired":false,"shares":997,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":913116,"source":{"system":"sec-edgar","filing":"0002065881-25-000013","document":"wk-form4_1749761587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000206588125000013/wk-form4_1749761587.xml","form_type":"4"}},{"id":1112804,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-12T20:53:13.000Z","date":"2025-06-10","kind":"gift","planned":false,"acquired":true,"shares":997,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by The John Franklin Watanabe Irrevocable Trust, of which the Reporting Person is the trustee."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of these securities for purposes of Section 16 or for any other purposes."}],"balance_after":25410,"source":{"system":"sec-edgar","filing":"0002065881-25-000013","document":"wk-form4_1749761587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000206588125000013/wk-form4_1749761587.xml","form_type":"4"}},{"id":1112803,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-12T20:53:13.000Z","date":"2025-06-10","kind":"gift","planned":false,"acquired":false,"shares":997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,315 shares purchased under Arcutis Biotherapeutics, Inc. Employee Stock Purchase Plan on May 31, 2025."}],"balance_after":914113,"source":{"system":"sec-edgar","filing":"0002065881-25-000013","document":"wk-form4_1749761587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000206588125000013/wk-form4_1749761587.xml","form_type":"4"}},{"id":1158547,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-05-05T21:20:25.000Z","date":"2025-05-02","kind":"sale","planned":true,"acquired":false,"shares":11448,"price":15.1919,"value":173916.8712,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\") granted on February 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.75 to $15.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":913795,"source":{"system":"sec-edgar","filing":"0001787306-25-000085","document":"wk-form4_1746480018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000085/wk-form4_1746480018.xml","form_type":"4"}},{"id":1190440,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-26T20:41:02.000Z","date":"2025-03-25","kind":"sale","planned":true,"acquired":false,"shares":2171,"price":17.564,"value":38131.444,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on  June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":925243,"source":{"system":"sec-edgar","filing":"0001787306-25-000050","document":"wk-form4_1743021655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000050/wk-form4_1743021655.xml","form_type":"4"}},{"id":1190439,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-26T20:41:02.000Z","date":"2025-03-24","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":17.5213,"value":26281.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on  June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.63, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":927414,"source":{"system":"sec-edgar","filing":"0001787306-25-000050","document":"wk-form4_1743021655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000050/wk-form4_1743021655.xml","form_type":"4"}},{"id":1195373,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-20T22:27:12.000Z","date":"2025-03-17","kind":"sale","planned":true,"acquired":false,"shares":1200,"price":17.6142,"value":21137.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on  June 14, 2024, by the Reporting Person, with a plan end date of September 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.5300 to $17.6600, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":928914,"source":{"system":"sec-edgar","filing":"0001787306-25-000048","document":"wk-form4_1742509625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000048/wk-form4_1742509625.xml","form_type":"4"}},{"id":1225835,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-05T00:43:54.000Z","date":"2025-02-28","kind":"grant","planned":true,"acquired":true,"shares":396000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":396000,"derivative":{"exercise_price":13.69,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":396000},"source":{"system":"sec-edgar","filing":"0001787306-25-000042","document":"wk-form4_1741135425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000042/wk-form4_1741135425.xml","form_type":"4"}},{"id":1225834,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-05T00:43:54.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":4135,"price":13.2841,"value":54929.7535,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.28 to $13.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective\nprice within the range set forth in this footnote."}],"balance_after":930114,"source":{"system":"sec-edgar","filing":"0001787306-25-000042","document":"wk-form4_1741135425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000042/wk-form4_1741135425.xml","form_type":"4"}},{"id":1225833,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-05T00:43:54.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":20880,"price":13.0311,"value":272089.368,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2022 and March 2, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.6902 to $13.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":934249,"source":{"system":"sec-edgar","filing":"0001787306-25-000042","document":"wk-form4_1741135425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000042/wk-form4_1741135425.xml","form_type":"4"}},{"id":1225832,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-05T00:43:54.000Z","date":"2025-02-28","kind":"grant","planned":true,"acquired":true,"shares":151000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the \"Vesting Commencement Date\"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":955129,"source":{"system":"sec-edgar","filing":"0001787306-25-000042","document":"wk-form4_1741135425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000042/wk-form4_1741135425.xml","form_type":"4"}},{"id":1283447,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-05T01:01:09.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":19301,"price":12.7,"value":245122.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the \"Vesting Commencement Date\"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.545 to $13.0096, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":804129,"source":{"system":"sec-edgar","filing":"0001787306-25-000016","document":"wk-form4_1738717263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000016/wk-form4_1738717263.xml","form_type":"4"}},{"id":1322505,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-24T00:22:12.000Z","date":"2024-12-20","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":15.1711,"value":227566.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on  June 14, 2024 by the Reporting Person, with a plan end date of  September 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.73, inclusive. The Reporting Person hereby\nundertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective\nprice within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the acquisition of 4,000 shares and 2,038 shares under the Company's Employee Stock Purchase Plan on May 31, 2024 and November 30, 2024, respectively, which transactions were exempt from Section 16(a) and (b) and were erroneously reported as non-exempt purchases in the Reporting Person's Form 4 filed on December 3, 2024."}],"balance_after":823430,"source":{"system":"sec-edgar","filing":"0001787306-24-000172","document":"wk-form4_1734999726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000172/wk-form4_1734999726.xml","form_type":"4"}},{"id":1344264,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-03T21:16:36.000Z","date":"2024-11-30","kind":"purchase","planned":false,"acquired":true,"shares":2038,"price":7.106,"value":14482.028,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan."}],"balance_after":838430,"source":{"system":"sec-edgar","filing":"0001787306-24-000166","document":"wk-form4_1733260588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000166/wk-form4_1733260588.xml","form_type":"4"}},{"id":1344263,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-03T21:16:36.000Z","date":"2024-05-31","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":1.692,"value":6768.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan."}],"balance_after":836392,"source":{"system":"sec-edgar","filing":"0001787306-24-000166","document":"wk-form4_1733260588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000166/wk-form4_1733260588.xml","form_type":"4"}},{"id":1374914,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-11-05T21:46:14.000Z","date":"2024-11-04","kind":"sale","planned":true,"acquired":false,"shares":13871,"price":8.6842,"value":120458.5382,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the Reporting Person's Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.32 to $8.86, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":832392,"source":{"system":"sec-edgar","filing":"0001787306-24-000144","document":"wk-form4_1730843166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000144/wk-form4_1730843166.xml","form_type":"4"}},{"id":1440324,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-05T20:37:14.000Z","date":"2024-08-02","kind":"sale","planned":true,"acquired":false,"shares":14487,"price":9.0183,"value":130648.1121,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.74 to $9.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":846263,"source":{"system":"sec-edgar","filing":"0001787306-24-000116","document":"wk-form4_1722890227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000116/wk-form4_1722890227.xml","form_type":"4"}},{"id":1527367,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-03T20:22:53.000Z","date":"2024-05-02","kind":"sale","planned":true,"acquired":false,"shares":13783,"price":8.7378,"value":120433.0974,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":860750,"source":{"system":"sec-edgar","filing":"0001787306-24-000070","document":"wk-form4_1714767763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000070/wk-form4_1714767763.xml","form_type":"4"}},{"id":1590693,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-03-06T22:09:59.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":14903,"price":11.1212,"value":165739.2436,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":874533,"source":{"system":"sec-edgar","filing":"0001787306-24-000038","document":"wk-form4_1709762984.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000038/wk-form4_1709762984.xml","form_type":"4"}},{"id":1605788,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-03-01T21:11:02.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":2465,"price":10.6,"value":26129.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units granted on  February 27, 2020."}],"balance_after":889436,"source":{"system":"sec-edgar","filing":"0001787306-24-000034","document":"wk-form4_1709327446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000034/wk-form4_1709327446.xml","form_type":"4"}},{"id":1640466,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":232200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in  twelve equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":0,"derivative":{"exercise_price":15.82,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":232200},"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1640465,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":188100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March  1, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":0,"derivative":{"exercise_price":17.67,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":188100},"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1640464,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":99200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":0,"derivative":{"exercise_price":32.44,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":99200},"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1640463,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option,  these Restricted Stock Units (\"RSUs\") that vest in four equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The canceled option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":27.61,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1640462,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":116100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in  twelve equal quarterly installments commencing May 1, 2024."}],"balance_after":891901,"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1640461,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":94050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."}],"balance_after":775801,"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1640460,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":33066,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."}],"balance_after":681751,"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1640459,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-15T23:30:44.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":21666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option,  these Restricted Stock Units (\"RSUs\") that vest in four equal quarterly installments commencing May 1, 2024."}],"balance_after":648685,"source":{"system":"sec-edgar","filing":"0001787306-24-000016","document":"wk-form4_1708039829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000016/wk-form4_1708039829.xml","form_type":"4"}},{"id":1677460,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-17T21:30:36.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":410000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":410000,"derivative":{"exercise_price":3.64,"expiration_date":"2034-01-12","underlying":"Common Stock","underlying_shares":410000},"source":{"system":"sec-edgar","filing":"0001787306-24-000006","document":"wk-form4_1705527025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000006/wk-form4_1705527025.xml","form_type":"4"}},{"id":1677459,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-17T21:30:36.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute Restricted Stock Units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on February 1, (the \"Vesting Commencement Date\"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":627019,"source":{"system":"sec-edgar","filing":"0001787306-24-000006","document":"wk-form4_1705527025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000006/wk-form4_1705527025.xml","form_type":"4"}},{"id":1700571,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-22T22:24:26.000Z","date":"2023-12-20","kind":"gift","planned":false,"acquired":true,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by The John Franklin Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust."}],"balance_after":24413,"source":{"system":"sec-edgar","filing":"0001787306-23-000134","document":"wk-form4_1703283856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000134/wk-form4_1703283856.xml","form_type":"4"}},{"id":1700570,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-22T22:24:26.000Z","date":"2023-12-20","kind":"gift","planned":false,"acquired":true,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust."}],"balance_after":24413,"source":{"system":"sec-edgar","filing":"0001787306-23-000134","document":"wk-form4_1703283856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000134/wk-form4_1703283856.xml","form_type":"4"}},{"id":1700569,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-22T22:24:26.000Z","date":"2023-12-20","kind":"gift","planned":false,"acquired":false,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":502019,"source":{"system":"sec-edgar","filing":"0001787306-23-000134","document":"wk-form4_1703283856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000134/wk-form4_1703283856.xml","form_type":"4"}},{"id":1700568,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-22T22:24:26.000Z","date":"2023-12-20","kind":"gift","planned":false,"acquired":false,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":508582,"source":{"system":"sec-edgar","filing":"0001787306-23-000134","document":"wk-form4_1703283856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000134/wk-form4_1703283856.xml","form_type":"4"}},{"id":1724985,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-02T01:51:36.000Z","date":"2023-12-01","kind":"exercise","planned":false,"acquired":false,"shares":59525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":49823,"derivative":{"exercise_price":1.6806,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":59525},"source":{"system":"sec-edgar","filing":"0001787306-23-000129","document":"wk-form4_1701481885.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000129/wk-form4_1701481885.xml","form_type":"4"}},{"id":1724984,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-02T01:51:36.000Z","date":"2023-05-31","kind":"purchase","planned":false,"acquired":true,"shares":1463,"price":6.38,"value":9333.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the purchase transaction of the Company's Employee Stock Purchase plan."}],"balance_after":515145,"source":{"system":"sec-edgar","filing":"0001787306-23-000129","document":"wk-form4_1701481885.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000129/wk-form4_1701481885.xml","form_type":"4"}},{"id":1724983,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-02T01:51:36.000Z","date":"2023-12-01","kind":"exercise","planned":false,"acquired":true,"shares":59525,"price":1.6806,"value":100037.715,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":513682,"source":{"system":"sec-edgar","filing":"0001787306-23-000129","document":"wk-form4_1701481885.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000129/wk-form4_1701481885.xml","form_type":"4"}},{"id":1933697,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-01T01:54:29.000Z","date":"2023-03-02","kind":"grant","planned":false,"acquired":true,"shares":232000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Amendment filed to add RSUs and Stock Options granted to Reporting Person on March 2, 2023. 1/48th  of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":232000,"derivative":{"exercise_price":15.82,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":232000},"source":{"system":"sec-edgar","filing":"0001787306-23-000025","document":"wf-form4a_168031405519295.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000025/wf-form4a_168031405519295.xml","form_type":"4/A","original_submission_date":"2023-02-28"}},{"id":1933696,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-04-01T01:54:29.000Z","date":"2023-03-02","kind":"grant","planned":false,"acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute Restricted Stock Units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, 25% of the RSUs vest annually on March 2 of each year, beginning on March 2, 2024, subject to the Reporting Person's continued service to the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects amount of securities beneficially owned as of March 2, 2023."}],"balance_after":456592,"source":{"system":"sec-edgar","filing":"0001787306-23-000025","document":"wf-form4a_168031405519295.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000025/wf-form4a_168031405519295.xml","form_type":"4/A","original_submission_date":"2023-02-28"}},{"id":1962454,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-08T21:29:57.000Z","date":"2023-03-06","kind":"sale","acquired":false,"shares":2435,"price":15.2638,"value":37167.353,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":366657,"source":{"system":"sec-edgar","filing":"0001567619-23-004672","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004672/doc1.xml","form_type":"4"}},{"id":1978364,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-03T00:06:40.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":69,"price":16.52,"value":1139.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":369092,"source":{"system":"sec-edgar","filing":"0001567619-23-004272","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004272/doc1.xml","form_type":"4"}},{"id":1978363,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-03T00:06:40.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":5403,"price":15.8182,"value":85465.7346,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":369161,"source":{"system":"sec-edgar","filing":"0001567619-23-004272","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004272/doc1.xml","form_type":"4"}},{"id":1978362,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-03T00:06:40.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":2343,"price":16.1663,"value":37877.6409,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":374564,"source":{"system":"sec-edgar","filing":"0001567619-23-004272","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004272/doc1.xml","form_type":"4"}},{"id":2013120,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-16T00:09:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":100,"price":17.03,"value":1703.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":376907,"source":{"system":"sec-edgar","filing":"0001787306-23-000008","document":"wf-form4_167650612269186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000008/wf-form4_167650612269186.xml","form_type":"4"}},{"id":2013119,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-16T00:09:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":417,"price":17.02,"value":7097.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":377007,"source":{"system":"sec-edgar","filing":"0001787306-23-000008","document":"wf-form4_167650612269186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000008/wf-form4_167650612269186.xml","form_type":"4"}},{"id":2013118,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-16T00:09:01.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":42,"price":17.01,"value":714.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":377424,"source":{"system":"sec-edgar","filing":"0001787306-23-000008","document":"wf-form4_167650612269186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000008/wf-form4_167650612269186.xml","form_type":"4"}},{"id":2013117,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-16T00:09:01.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":441,"price":17,"value":7497.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":377466,"source":{"system":"sec-edgar","filing":"0001787306-23-000008","document":"wf-form4_167650612269186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000008/wf-form4_167650612269186.xml","form_type":"4"}},{"id":2031852,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-03T21:26:04.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":382,"price":17,"value":6494.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":377907,"source":{"system":"sec-edgar","filing":"0001787306-23-000006","document":"wf-form4_167545953621023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000006/wf-form4_167545953621023.xml","form_type":"4"}},{"id":2031851,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-03T21:26:04.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":618,"price":17.0044,"value":10508.7192,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":378289,"source":{"system":"sec-edgar","filing":"0001787306-23-000006","document":"wf-form4_167545953621023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000006/wf-form4_167545953621023.xml","form_type":"4"}},{"id":2090734,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-09T21:47:32.000Z","date":"2022-12-07","kind":"sale","acquired":false,"shares":1000,"price":17.06,"value":17060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":378907,"source":{"system":"sec-edgar","filing":"0001787306-22-000079","document":"wf-form4_167062242477432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000079/wf-form4_167062242477432.xml","form_type":"4"}},{"id":2120809,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-11-09T21:39:39.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":1000,"price":18.004,"value":18004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.94 to $18.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 109,925 Restricted Stock Units."}],"balance_after":379907,"source":{"system":"sec-edgar","filing":"0001787306-22-000073","document":"wf-form4_166802996099874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000073/wf-form4_166802996099874.xml","form_type":"4"}},{"id":2138896,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-11T22:47:04.000Z","date":"2022-10-07","kind":"sale","acquired":false,"shares":1000,"price":19.51,"value":19510.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":380907,"source":{"system":"sec-edgar","filing":"0001567619-22-018418","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922018418/doc1.xml","form_type":"4"}},{"id":2161960,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-09T21:10:28.000Z","date":"2022-09-07","kind":"sale","acquired":false,"shares":1000,"price":21.51,"value":21510.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 109,925 restricted stock units."}],"balance_after":381907,"source":{"system":"sec-edgar","filing":"0001567619-22-017237","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922017237/doc1.xml","form_type":"4"}},{"id":2161959,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-09T21:10:28.000Z","date":"2022-06-23","kind":"gift","acquired":false,"shares":268964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 109,925 restricted stock units."}],"balance_after":382907,"source":{"system":"sec-edgar","filing":"0001567619-22-017237","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922017237/doc1.xml","form_type":"4"}},{"id":2190377,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-09T21:16:12.000Z","date":"2022-08-05","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":109348,"derivative":{"exercise_price":1.6806,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001567619-22-015354","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922015354/doc1.xml","form_type":"4"}},{"id":2190376,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-09T21:16:12.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":2500,"price":24.7432,"value":61858.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $24.35 to $25.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":651871,"source":{"system":"sec-edgar","filing":"0001567619-22-015354","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922015354/doc1.xml","form_type":"4"}},{"id":2190375,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-09T21:16:12.000Z","date":"2022-08-05","kind":"exercise","acquired":true,"shares":2500,"price":1.6806,"value":4201.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":654371,"source":{"system":"sec-edgar","filing":"0001567619-22-015354","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922015354/doc1.xml","form_type":"4"}},{"id":2208406,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-12T23:30:26.000Z","date":"2022-07-08","kind":"exercise","acquired":false,"shares":7087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":111848,"derivative":{"exercise_price":1.6806,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":7087},"source":{"system":"sec-edgar","filing":"0001567619-22-013924","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922013924/doc1.xml","form_type":"4"}},{"id":2208405,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-12T23:30:26.000Z","date":"2022-07-08","kind":"sale","acquired":false,"shares":7087,"price":25.4144,"value":180111.8528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $25.00 to $25.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":651871,"source":{"system":"sec-edgar","filing":"0001567619-22-013924","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922013924/doc1.xml","form_type":"4"}},{"id":2208404,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-12T23:30:26.000Z","date":"2022-07-08","kind":"exercise","acquired":true,"shares":7087,"price":1.6806,"value":11910.4122,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":658958,"source":{"system":"sec-edgar","filing":"0001567619-22-013924","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922013924/doc1.xml","form_type":"4"}},{"id":2208403,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-12T23:30:26.000Z","date":"2022-07-08","kind":"sale","acquired":false,"shares":4913,"price":25.4144,"value":124860.9472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $25.00 to $25.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":651871,"source":{"system":"sec-edgar","filing":"0001567619-22-013924","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922013924/doc1.xml","form_type":"4"}},{"id":2208402,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-12T23:30:26.000Z","date":"2022-07-08","kind":"sale","acquired":false,"shares":1500,"price":25,"value":37500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":656784,"source":{"system":"sec-edgar","filing":"0001567619-22-013924","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922013924/doc1.xml","form_type":"4"}},{"id":2210448,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-07T20:04:23.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":1000,"price":22.07,"value":22070.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":658284,"source":{"system":"sec-edgar","filing":"0001567619-22-013783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922013783/doc1.xml","form_type":"4"}},{"id":2241103,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-06-06T20:06:50.000Z","date":"2022-06-06","kind":"sale","acquired":false,"shares":1000,"price":21.064,"value":21064.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $20.84 to $21.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the purchase of 1,617 shares under the Arcutis Employee Stock Purchase Plan on May 31, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 109,925 restricted stock units."}],"balance_after":659284,"source":{"system":"sec-edgar","filing":"0001567619-22-012377","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922012377/doc1.xml","form_type":"4"}},{"id":2280458,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-05T21:31:56.000Z","date":"2022-05-05","kind":"sale","acquired":false,"shares":1000,"price":21.76,"value":21760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":658667,"source":{"system":"sec-edgar","filing":"0001567619-22-009639","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922009639/doc1.xml","form_type":"4"}},{"id":2303247,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-05T22:45:50.000Z","date":"2022-04-05","kind":"sale","acquired":false,"shares":1000,"price":21.43,"value":21430.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units."}],"balance_after":659667,"source":{"system":"sec-edgar","filing":"0001567619-22-008131","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922008131/doc1.xml","form_type":"4"}},{"id":2337075,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-12T02:42:23.000Z","date":"2022-03-09","kind":"sale","acquired":false,"shares":300,"price":17,"value":5100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,925 restricted stock units \"RSUs\". The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":660667,"source":{"system":"sec-edgar","filing":"0000899243-22-010801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000089924322010801/doc4.xml","form_type":"4"}},{"id":2346914,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-08T01:59:52.000Z","date":"2022-03-07","kind":"exercise","acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":118935,"derivative":{"exercise_price":1.6806,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001567619-22-006498","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006498/doc1.xml","form_type":"4"}},{"id":2346913,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-08T01:59:52.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":188100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":188100,"derivative":{"exercise_price":17.67,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":188100},"source":{"system":"sec-edgar","filing":"0001567619-22-006498","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006498/doc1.xml","form_type":"4"}},{"id":2346912,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-08T01:59:52.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":700,"price":17.1058,"value":11974.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades in prices ranging from $17.02 to $17.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 109,925 restricted stock units."}],"balance_after":660967,"source":{"system":"sec-edgar","filing":"0001567619-22-006498","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006498/doc1.xml","form_type":"4"}},{"id":2346911,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-08T01:59:52.000Z","date":"2022-03-07","kind":"exercise","acquired":true,"shares":700,"price":1.6806,"value":1176.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":661667,"source":{"system":"sec-edgar","filing":"0001567619-22-006498","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006498/doc1.xml","form_type":"4"}},{"id":2346910,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-08T01:59:52.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":70,"price":16.4449,"value":1151.143,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":660967,"source":{"system":"sec-edgar","filing":"0001567619-22-006498","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006498/doc1.xml","form_type":"4"}},{"id":2346909,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-08T01:59:52.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":2489,"price":16.8591,"value":41962.2999,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":661037,"source":{"system":"sec-edgar","filing":"0001567619-22-006498","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006498/doc1.xml","form_type":"4"}},{"id":2346908,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-08T01:59:52.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":70900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":663526,"source":{"system":"sec-edgar","filing":"0001567619-22-006498","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006498/doc1.xml","form_type":"4"}},{"id":2352237,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-03T21:18:42.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":2153,"price":17.7527,"value":38221.5631,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 47,200 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":592626,"source":{"system":"sec-edgar","filing":"0001567619-22-006230","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006230/doc1.xml","form_type":"4"}},{"id":2400929,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-11T22:55:19.000Z","date":"2022-02-09","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":119635,"derivative":{"exercise_price":1.6806,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001567619-22-003692","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922003692/doc1.xml","form_type":"4"}},{"id":2400928,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-11T22:55:19.000Z","date":"2022-02-09","kind":"sale","acquired":false,"shares":1000,"price":17,"value":17000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":594779,"source":{"system":"sec-edgar","filing":"0001567619-22-003692","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922003692/doc1.xml","form_type":"4"}},{"id":2400927,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-11T22:55:19.000Z","date":"2022-02-09","kind":"exercise","acquired":true,"shares":1000,"price":1.6806,"value":1680.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":595779,"source":{"system":"sec-edgar","filing":"0001567619-22-003692","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922003692/doc1.xml","form_type":"4"}},{"id":2439607,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-07T21:17:39.000Z","date":"2022-01-05","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":120635,"derivative":{"exercise_price":1.6806,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001567619-22-000851","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922000851/doc1.xml","form_type":"4"}},{"id":2439606,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-07T21:17:39.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":600,"price":21.11,"value":12666.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":594779,"source":{"system":"sec-edgar","filing":"0001567619-22-000851","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922000851/doc1.xml","form_type":"4"}},{"id":2439605,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":26125,"kind":"person","name":"Watanabe Todd","position":1,"cik":"0001801061","reported_name":"Watanabe Todd Franklin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-07T21:17:39.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":100,"price":22.06,"value":2206.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":595379,"source":{"system":"sec-edgar","filing":"0001567619-22-000851","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922000851/doc1.xml","form_type":"4"}}],"next_cursor":"2022-01-07T21:17:39.000000Z,2439605"}